Evaluation of the dose enhancement of combined 10B + 157Gd neutron capture therapy (NCT)

N. Protti; S. Geninatti-Crich; D. Alberti; S. Lanzardo; A. Deagostino; A. Toppino; S. Aime; F. Ballarini; S. Bortolussi; P. Bruschi; I. Postuma; S. Altieri; H. Nikjoo

doi:10.1093/rpd/ncv300

Evaluation of the dose enhancement of combined ¹⁰B + ¹⁵⁷Gd neutron capture therapy (NCT)

N. Protti, S. Geninatti-Crich, D. Alberti, S. Lanzardo, A. Deagostino, A. Toppino, S. Aime, F. Ballarini, S. Bortolussi, P. Bruschi, I. Postuma, S. Altieri, H. Nikjoo

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

An innovative molecule, GdBLDL, for boron neutron capture therapy (BNCT) has been developed and its effectiveness as a BNCT carrier is currently under evaluation using in vivo experiments on small animal tumour models. The molecule contains both ¹⁰B (the most commonly used NCT agent) and ¹⁵⁷Gd nuclei. ¹⁵⁷Gd is the second most studied element to perform NCT, mainly thanks to its high cross section for the capture of low-energy neutrons. The main drawbackof ¹⁵⁷Gd neutron capture reaction is the very short range and low-energy secondary charged particles (Auger electrons), which requires ¹⁵⁷Gd to be very close to the cellular DNA to have an appreciable biological effect. Treatment doses were calculated by Monte Carlo simulations to ensure the optimised tumour irradiation and the sparing of the healthy organs of the irradiated animals. The enhancement of the absorbed dose due to the simultaneous presence of ¹⁰B and ¹⁵⁷Gd in the experimental set-up was calculated and the advantage introduced by the presence of ¹⁵⁷Gd was discussed.

Original language	English
Pages (from-to)	369-373
Number of pages	5
Journal	Radiation Protection Dosimetry
Volume	166
Issue number	1-4
DOIs	https://doi.org/10.1093/rpd/ncv300
Publication status	Published - Sep 1 2015
Externally published	Yes

ASJC Scopus subject areas

Radiation
Radiological and Ultrasound Technology
Radiology Nuclear Medicine and imaging
Public Health, Environmental and Occupational Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/rpd/ncv300

Cite this

Evaluation of the dose enhancement of combined ¹⁰B + ¹⁵⁷Gd neutron capture therapy (NCT). / Protti, N.; Geninatti-Crich, S.; Alberti, D.; Lanzardo, S.; Deagostino, A.; Toppino, A.; Aime, S.; Ballarini, F.; Bortolussi, S.; Bruschi, P.; Postuma, I.; Altieri, S.; Nikjoo, H.

In: Radiation Protection Dosimetry, Vol. 166, No. 1-4, 01.09.2015, p. 369-373.

Research output: Contribution to journal › Article › peer-review

@article{ef42b06017184a7d88c38a1488a76cea,

title = "Evaluation of the dose enhancement of combined 10B + 157Gd neutron capture therapy (NCT)",

abstract = "An innovative molecule, GdBLDL, for boron neutron capture therapy (BNCT) has been developed and its effectiveness as a BNCT carrier is currently under evaluation using in vivo experiments on small animal tumour models. The molecule contains both 10B (the most commonly used NCT agent) and 157Gd nuclei. 157Gd is the second most studied element to perform NCT, mainly thanks to its high cross section for the capture of low-energy neutrons. The main drawbackof 157Gd neutron capture reaction is the very short range and low-energy secondary charged particles (Auger electrons), which requires 157Gd to be very close to the cellular DNA to have an appreciable biological effect. Treatment doses were calculated by Monte Carlo simulations to ensure the optimised tumour irradiation and the sparing of the healthy organs of the irradiated animals. The enhancement of the absorbed dose due to the simultaneous presence of 10B and 157Gd in the experimental set-up was calculated and the advantage introduced by the presence of 157Gd was discussed.",

author = "N. Protti and S. Geninatti-Crich and D. Alberti and S. Lanzardo and A. Deagostino and A. Toppino and S. Aime and F. Ballarini and S. Bortolussi and P. Bruschi and I. Postuma and S. Altieri and H. Nikjoo",

note = "Publisher Copyright: {\textcopyright} The Author 2015.",

year = "2015",

month = sep,

day = "1",

doi = "10.1093/rpd/ncv300",

language = "English",

volume = "166",

pages = "369--373",

journal = "Radiation Protection Dosimetry",

issn = "0144-8420",

publisher = "Oxford University Press",

number = "1-4",

}

TY - JOUR

T1 - Evaluation of the dose enhancement of combined 10B + 157Gd neutron capture therapy (NCT)

AU - Protti, N.

AU - Geninatti-Crich, S.

AU - Alberti, D.

AU - Lanzardo, S.

AU - Deagostino, A.

AU - Toppino, A.

AU - Aime, S.

AU - Ballarini, F.

AU - Bortolussi, S.

AU - Bruschi, P.

AU - Postuma, I.

AU - Altieri, S.

AU - Nikjoo, H.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - An innovative molecule, GdBLDL, for boron neutron capture therapy (BNCT) has been developed and its effectiveness as a BNCT carrier is currently under evaluation using in vivo experiments on small animal tumour models. The molecule contains both 10B (the most commonly used NCT agent) and 157Gd nuclei. 157Gd is the second most studied element to perform NCT, mainly thanks to its high cross section for the capture of low-energy neutrons. The main drawbackof 157Gd neutron capture reaction is the very short range and low-energy secondary charged particles (Auger electrons), which requires 157Gd to be very close to the cellular DNA to have an appreciable biological effect. Treatment doses were calculated by Monte Carlo simulations to ensure the optimised tumour irradiation and the sparing of the healthy organs of the irradiated animals. The enhancement of the absorbed dose due to the simultaneous presence of 10B and 157Gd in the experimental set-up was calculated and the advantage introduced by the presence of 157Gd was discussed.

AB - An innovative molecule, GdBLDL, for boron neutron capture therapy (BNCT) has been developed and its effectiveness as a BNCT carrier is currently under evaluation using in vivo experiments on small animal tumour models. The molecule contains both 10B (the most commonly used NCT agent) and 157Gd nuclei. 157Gd is the second most studied element to perform NCT, mainly thanks to its high cross section for the capture of low-energy neutrons. The main drawbackof 157Gd neutron capture reaction is the very short range and low-energy secondary charged particles (Auger electrons), which requires 157Gd to be very close to the cellular DNA to have an appreciable biological effect. Treatment doses were calculated by Monte Carlo simulations to ensure the optimised tumour irradiation and the sparing of the healthy organs of the irradiated animals. The enhancement of the absorbed dose due to the simultaneous presence of 10B and 157Gd in the experimental set-up was calculated and the advantage introduced by the presence of 157Gd was discussed.

UR - http://www.scopus.com/inward/record.url?scp=84941759263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941759263&partnerID=8YFLogxK

U2 - 10.1093/rpd/ncv300

DO - 10.1093/rpd/ncv300

M3 - Article

C2 - 26246584

AN - SCOPUS:84941759263

VL - 166

SP - 369

EP - 373

JO - Radiation Protection Dosimetry

JF - Radiation Protection Dosimetry

SN - 0144-8420

IS - 1-4

ER -